Professor Kehoe adds: ‘It would make sense that systems which drive cell growth [as in cancer] are protective against a ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Researchers from the International Working Group recommend categorizing biomarker-positive, cognitively normal individuals as ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The following is a summary of “Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From ...

"We showed people with Alzheimer's disease have more gut inflammation," University of Wisconsin psychologist Barbara Bendlin ...

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

As the disease progresses to moderate dementia, damage in areas of the brain that control language, reasoning, conscious thought, and sensory processing lead to more severe symptoms.

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.